Cargando…

Safety and efficacy of newer biologics DMARDs in the management of rheumatoid arthritis: A systematic review

OBJECTIVE: To analyze the safety and efficacy of certain biologics DMARDs (Adalimumab, Baricitinib, Pefacitinib and Sirukumab) either used alone or as a combination with MTX for management of rheumatoid arthritis. METHOD: We conducted a systematic literature review on various phase 3 Randomized cont...

Descripción completa

Detalles Bibliográficos
Autores principales: Zago, Basiru Ahmad, Priyadharshini, A., Vijayakumar, T.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718147/
https://www.ncbi.nlm.nih.gov/pubmed/36474893
http://dx.doi.org/10.1016/j.ocarto.2020.100116
_version_ 1784843027047514112
author Zago, Basiru Ahmad
Priyadharshini, A.
Vijayakumar, T.M.
author_facet Zago, Basiru Ahmad
Priyadharshini, A.
Vijayakumar, T.M.
author_sort Zago, Basiru Ahmad
collection PubMed
description OBJECTIVE: To analyze the safety and efficacy of certain biologics DMARDs (Adalimumab, Baricitinib, Pefacitinib and Sirukumab) either used alone or as a combination with MTX for management of rheumatoid arthritis. METHOD: We conducted a systematic literature review on various phase 3 Randomized controlled trails, double blind, placebo controlled, parallel group clinical trials for 52 weeks from 2017 to 2019 conforming to the Preferred Reporting Items for Systematic reviews and Meta-Analysis guidelines. The primary efficacy endpoints were American College of Rheumatology 20 response rate improvement criteria, other secondary endpoints were American College of Rheumatology 50/70 response rates, Health Assessment Questionnaire Disability Index, Disease Activity Score-28 for rheumatoid arthritis with Erythrocyte Sedimentation Rate/C Reactive Protein and Radiographic outcomes. RESULTS: Finally, four studies were included for qualitative synthesis in which we observed improvement in ACR 20 response rate was found in the newer agents study group. SB5 (72.4%) at week 24, Baricitinib (70%) at week 12, Pefacitinib 100 mg and 150 mg (57.7% & 74.5%) at week 12 and Sirukumab 50 mg and 100 mg (55% & 54%) at week 16 respectively. ACR 50 and ACR 70 response rate at different point in time was also found to be higher in the study group which indicates their efficacy. CONCLUSION: In this systematic review, we observed an improvement in ACR 20 response rate and other secondary efficacy outcomes with an acceptable safety margin. From the evidence of RCTs, we have identified that newer therapeutic agents has beneficial effects when compared to existing therapy.
format Online
Article
Text
id pubmed-9718147
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-97181472022-12-05 Safety and efficacy of newer biologics DMARDs in the management of rheumatoid arthritis: A systematic review Zago, Basiru Ahmad Priyadharshini, A. Vijayakumar, T.M. Osteoarthr Cartil Open REVIEW OBJECTIVE: To analyze the safety and efficacy of certain biologics DMARDs (Adalimumab, Baricitinib, Pefacitinib and Sirukumab) either used alone or as a combination with MTX for management of rheumatoid arthritis. METHOD: We conducted a systematic literature review on various phase 3 Randomized controlled trails, double blind, placebo controlled, parallel group clinical trials for 52 weeks from 2017 to 2019 conforming to the Preferred Reporting Items for Systematic reviews and Meta-Analysis guidelines. The primary efficacy endpoints were American College of Rheumatology 20 response rate improvement criteria, other secondary endpoints were American College of Rheumatology 50/70 response rates, Health Assessment Questionnaire Disability Index, Disease Activity Score-28 for rheumatoid arthritis with Erythrocyte Sedimentation Rate/C Reactive Protein and Radiographic outcomes. RESULTS: Finally, four studies were included for qualitative synthesis in which we observed improvement in ACR 20 response rate was found in the newer agents study group. SB5 (72.4%) at week 24, Baricitinib (70%) at week 12, Pefacitinib 100 mg and 150 mg (57.7% & 74.5%) at week 12 and Sirukumab 50 mg and 100 mg (55% & 54%) at week 16 respectively. ACR 50 and ACR 70 response rate at different point in time was also found to be higher in the study group which indicates their efficacy. CONCLUSION: In this systematic review, we observed an improvement in ACR 20 response rate and other secondary efficacy outcomes with an acceptable safety margin. From the evidence of RCTs, we have identified that newer therapeutic agents has beneficial effects when compared to existing therapy. Elsevier 2020-11-01 /pmc/articles/PMC9718147/ /pubmed/36474893 http://dx.doi.org/10.1016/j.ocarto.2020.100116 Text en © 2020 Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International (OARSI). https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle REVIEW
Zago, Basiru Ahmad
Priyadharshini, A.
Vijayakumar, T.M.
Safety and efficacy of newer biologics DMARDs in the management of rheumatoid arthritis: A systematic review
title Safety and efficacy of newer biologics DMARDs in the management of rheumatoid arthritis: A systematic review
title_full Safety and efficacy of newer biologics DMARDs in the management of rheumatoid arthritis: A systematic review
title_fullStr Safety and efficacy of newer biologics DMARDs in the management of rheumatoid arthritis: A systematic review
title_full_unstemmed Safety and efficacy of newer biologics DMARDs in the management of rheumatoid arthritis: A systematic review
title_short Safety and efficacy of newer biologics DMARDs in the management of rheumatoid arthritis: A systematic review
title_sort safety and efficacy of newer biologics dmards in the management of rheumatoid arthritis: a systematic review
topic REVIEW
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718147/
https://www.ncbi.nlm.nih.gov/pubmed/36474893
http://dx.doi.org/10.1016/j.ocarto.2020.100116
work_keys_str_mv AT zagobasiruahmad safetyandefficacyofnewerbiologicsdmardsinthemanagementofrheumatoidarthritisasystematicreview
AT priyadharshinia safetyandefficacyofnewerbiologicsdmardsinthemanagementofrheumatoidarthritisasystematicreview
AT vijayakumartm safetyandefficacyofnewerbiologicsdmardsinthemanagementofrheumatoidarthritisasystematicreview